An open-label extension study to evaluate safety and efficacy of Pazopanib in patients with advanced renal cell carcinoma.
Affiliation1Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy
MetadataShow full item record
AbstractEvaluation of the safety and efficacy of pazopanib, a multikinase angiogenesis inhibitor, in a single-arm, open-label, extension study (VEG107769/NCT00387764) for placebo-treated patients with advanced renal cell carcinoma (RCC) from a randomized, double-blind, placebo-controlled phase III study (VEG105192/NCT00334282).
CitationAn open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma. 2014, 87 (6):342-50 Oncology